Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol
about
Long-acting muscarinic antagonist plus long-acting beta agonist versus long-acting beta agonist plus inhaled corticosteroid for stable chronic obstructive pulmonary diseaseLong-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysisLong-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled studyPatient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol.Antihypertensive Combination Treatment: State of the Art.Bronchodilators, receptors and cross-talk: Together is better?Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid.Vilanterol trifenatate for the treatment of COPD.Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol.
P2860
Q24186227-159E89D1-E975-4B52-A98A-BF51400180E0Q26800134-8207CA8F-6DF3-4F4F-A739-564F9A96D617Q30238494-7453F1DA-48BA-4D36-996F-FED176C7514AQ36036894-586F1CFE-1302-465C-9B6D-C5A61D083A55Q38352425-9978CE6C-832B-4450-AE30-7ED144B47258Q38525960-7549746A-3068-42C3-BC87-43FE5753CDC1Q38570698-C849FEAA-7767-4F7E-8282-84ABC1DB303BQ38690660-75E3BF92-F6AB-42EC-AC59-FE9E3A967969Q38693424-EC82BFD3-58C6-40E9-9BAD-946A0C118EEEQ38824916-5A54D602-E1EB-430C-B4BC-15C6FB1B03D8Q38947859-7761F6E6-CA34-4F44-97E6-2093447C14DDQ55360310-FF6D241E-6DAE-46A9-86AD-A7FA2C4AA845
P2860
Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD--role of umeclidinium/vilanterol
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Differential pharmacology and ...... ole of umeclidinium/vilanterol
@ast
Differential pharmacology and ...... ole of umeclidinium/vilanterol
@en
Differential pharmacology and ...... ole of umeclidinium/vilanterol
@nl
type
label
Differential pharmacology and ...... ole of umeclidinium/vilanterol
@ast
Differential pharmacology and ...... ole of umeclidinium/vilanterol
@en
Differential pharmacology and ...... ole of umeclidinium/vilanterol
@nl
prefLabel
Differential pharmacology and ...... ole of umeclidinium/vilanterol
@ast
Differential pharmacology and ...... ole of umeclidinium/vilanterol
@en
Differential pharmacology and ...... ole of umeclidinium/vilanterol
@nl
P2860
P921
P356
P1476
Differential pharmacology and ...... ole of umeclidinium/vilanterol
@en
P2093
Alessandro Radaeli
Jaymin Bhagwanji Morjaria
P2860
P304
P356
10.2147/COPD.S47792
P407
P50
P577
2014-01-01T00:00:00Z
2014-06-27T00:00:00Z